Abstract
Factor V Leiden thrombophilia is a genetic disorder that may increase a patient's risk of developing a venous thromboembolism (VTE). Current management strategies involve the use of pharmacotherapy, when indicated, in the event of deep venous thrombosis or pulmonary embolism. Treatment guidelines have specific recommendations regarding the use of oral anticoagulant therapy for the treatment and prevention of VTE events. Pharmacotherapy options include vitamin K antagonists or direct oral anticoagulants, such as direct thrombin inhibitors, and factor Xa inhibitors. Owing to multiple considerations concerning site and cause of the VTE, it can be daunting to select an agent. Understanding the therapy options for factor V Leiden will be beneficial for pharmacists who have the opportunity to answer questions and provide patient counseling about this disease.